Screening, supplements and the use of hormonal replacement therapy in postmenopausal women in a family medicine department prior to the publication of the Woman's Health Initiative report
- PMID: 15307453
- PMCID: PMC6147931
- DOI: 10.5144/0256-4947.2004.175
Screening, supplements and the use of hormonal replacement therapy in postmenopausal women in a family medicine department prior to the publication of the Woman's Health Initiative report
Abstract
Background: Many guidelines and recommendations exist on the management of the menopause. Because it is not certain what women do or what management they receive in practice, we studied what was prescribed for postmenopausal women and what screening they had undergone.
Patients and methods: A retrospective chart review was conducted on all postmenopausal women between the ages of 56-59 years who had no absolute contraindications to taking hormonal replacement therapy (HRT) and were frequent enough attendees at the family health clinic to ensure that postmenopausal issues had been addressed and screening and follow up performed. The women were patients of the family medicine department at a tertiary care hospital in Saudi Arabia.
Results: Sixty-one percent had taken HRT at some time after the menopause, including 42% of Saudis and 87% of non-Saudis. Forty-six percent of all women were taking HRT at the time of the study, including 30% of Saudis and 70% of non-Saudis. Fifty-one percent of all women were taking calcium supplements, 49% were taking vitamin D supplementation, and 63% had undergone a bone mineral density evaluation. There were notable differences in percentages between Saudis and non-Saudis. Sixteen percent of all women had never had a mammogram, including 26% of Saudis and only 3% of non-Saudis.
Conclusion: Many postmenopausal women with access to medical care were not screened nor were they taking supplements in accordance with published guidelines. There was a discrepancy in the management of Saudi and non-Saudi women that could be explained partially by the high percentage of medical professionals among non-Saudi women who are more likely to actively seek medical attention. Our study showed a large proportion of women on HRT, the standard of care before the publication of the Women's Health Initiative study.
Figures
Comment in
-
Evidence-based medicine and hormone replacement therapy.Ann Saudi Med. 2004 May-Jun;24(3):164-5. doi: 10.5144/0256-4947.2004.164. Ann Saudi Med. 2004. PMID: 15307450 Free PMC article. No abstract available.
Similar articles
-
Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial.J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):460-2. doi: 10.1093/gerona/60.4.460. J Gerontol A Biol Sci Med Sci. 2005. PMID: 15933383
-
Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials.Menopause. 2017 Apr;24(4):371-378. doi: 10.1097/GME.0000000000000775. Menopause. 2017. PMID: 27801706 Free PMC article. Clinical Trial.
-
Questionnaire survey of women aged 56-59 years: consultations in general practice, use of hormone replacement therapy (HRT) and participation in screening programmes.J Fam Plann Reprod Health Care. 2002 Jan;28(1):15-7. doi: 10.1783/147118902101195947. J Fam Plann Reprod Health Care. 2002. PMID: 16259809
-
Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative.J Manag Care Pharm. 2008 Apr;14(3 Suppl):7-13. doi: 10.18553/jmcp.2008.14.S3-A.7. J Manag Care Pharm. 2008. PMID: 18439061 Free PMC article. Review.
-
The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society.Menopause. 2006 Nov-Dec;13(6):862-77; quiz 878-80. doi: 10.1097/01.gme.0000243566.25205.0b. Menopause. 2006. PMID: 17106282
Cited by
-
The present and the future of breast cancer burden in the Kingdom of Saudi Arabia.Med Oncol. 2008;25(4):387-93. doi: 10.1007/s12032-008-9051-5. Epub 2008 Mar 4. Med Oncol. 2008. PMID: 18317955
References
-
- US Agency for Healthcare research and Quality. National Guideline Clearinghouse. [accessed 4 May 2003]. http://www.guideline.gov.
-
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. - PubMed
-
- Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55–72. - PubMed
-
- Grady D, Rubin S, Petitti D, Fox CS, Black D, Ettingher B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037. - PubMed
-
- Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prep Med. 1991;20:47–63. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical